7-<(3-chloropropyl)oxy>-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid ethyl ester | 155219-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-<(3-chloropropyl)oxy>-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid ethyl ester
• 英文别名: Ethyl 7-(3-chloropropoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylate；ethyl 7-(3-chloropropoxy)-8-propyl-3,4-dihydro-2H-chromene-2-carboxylate
• CAS: 155219-33-3
• 化学式: C₁₈H₂₅ClO₄
• 分子量: 340.847
• InChiKey: HRGWGIDZLNRQGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-<(3-chloropropyl)oxy>-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid ethyl ester 在 potassium carbonate 、 potassium iodide 作用下， 以 二甲基亚砜 、 丁酮 为溶剂， 反应 21.5h， 生成 7-{3-[4-((Z)-3-Dimethylamino-acryloyl)-2-ethyl-5-hydroxy-phenoxy]-propoxy}-8-propyl-chroman-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Leukotriene B4 (LTB4) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles

  摘要：

  A series of (hydroxyphenyl)pyrazoles was designed by molecular modeling comparison with the LTB(4) structure and prepared for evaluation as LTB(4) receptor antagonists, culminating in 4-ethyl-5-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]-2-(1H-pyrazol-3-yl)phenyl (2). Using an assay for inhibition of specific [H-3]LTB(4) binding to human PMN, it was found that the pyrazole ring could be methylated at N(1) with little loss of activity while methylation at N(2) reduced activity significantly. The structure-activity relationship of the terminal acid group was investigated. Good activity was found with o- and m-phenylalkanoic acids, chromane carboxylic acid, and tetrazole groups. The best in vitro activity was realized with the pyrazole nitrogen unsubstituted and with a six-carbon chain linking the phenyl ether oxygen to the tetrazole group. Compound 2, having an IC50 of 6.4 +/- 0.8 nM in the binding assay, was selected for further preclinical evaluation.

  DOI：

  10.1021/jm00041a021
• 作为产物：
  描述：

  7-hydroxy-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid ethyl ester 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、358.53 kPa 条件下， 反应 43.0h， 生成 7-<(3-chloropropyl)oxy>-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Leukotriene B4 (LTB4) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles

  摘要：

  A series of (hydroxyphenyl)pyrazoles was designed by molecular modeling comparison with the LTB(4) structure and prepared for evaluation as LTB(4) receptor antagonists, culminating in 4-ethyl-5-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]-2-(1H-pyrazol-3-yl)phenyl (2). Using an assay for inhibition of specific [H-3]LTB(4) binding to human PMN, it was found that the pyrazole ring could be methylated at N(1) with little loss of activity while methylation at N(2) reduced activity significantly. The structure-activity relationship of the terminal acid group was investigated. Good activity was found with o- and m-phenylalkanoic acids, chromane carboxylic acid, and tetrazole groups. The best in vitro activity was realized with the pyrazole nitrogen unsubstituted and with a six-carbon chain linking the phenyl ether oxygen to the tetrazole group. Compound 2, having an IC50 of 6.4 +/- 0.8 nM in the binding assay, was selected for further preclinical evaluation.

  DOI：

  10.1021/jm00041a021

文献信息

• Leukotriene B.sub.4 antagonists
  申请人：Eli Lilly and Company

  公开号：US05324743A1

  公开（公告）日：1994-06-28

  This invention provides certain 1,2,4,5 substituted benzene derivatives containing "acid" substituents derived from cyclic or heterocyclic moieties. These unique compounds are leukotriene B.sub.4 antagonists and formulations of these derivatives, and a method of using these derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

  这项发明提供了含有来自环状或杂环基团的“酸”取代基的某些1,2,4,5取代苯衍生物。这些独特化合物是白三烯B.sub.4拮抗剂，以及这些衍生物的配方，以及使用这些衍生物治疗由白三烯过度释放引起的疾病的方法。
• Use of PLA.sub.2 inhibitors as treatment for alzheimer's disease
  申请人：Eli Lilly and Company

  公开号：US05478857A1

  公开（公告）日：1995-12-26

  This invention provides methods for the treatment or prevention of Alzheimer's disease in a mammal which comprises administering to a mammal in need thereof an effective amount of an inhibitor of phospholipase A.sub.2. This invention also provides a series of compounds which are useful as inhibitors of phospholipases A.sub.2, especially cytosolic phospholipase A.sub.2.

  该发明提供了治疗或预防哺乳动物阿尔茨海默病的方法，包括向需要的哺乳动物施用磷脂酶A.sub.2的抑制剂的有效量。该发明还提供了一系列化合物，这些化合物可用作磷脂酶A.sub.2的抑制剂，尤其是细胞质磷脂酶A.sub.2。
• [EN] USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE<br/>[FR] UTILISATION D'INHIBITEURS DE PLA2 POUR TRAITER LA MALADIE D'ALZHEIMER
  申请人：ELI LILLY AND COMPANY

  公开号：WO1995017183A1

  公开（公告）日：1995-06-29

  (EN) This invention provides methods for the treatment or prevention of Alzheimer's disease in a mammal which comprises administering to a mammal in need thereof an effective amount of an inhibitor of phospholipase A2. This invention also provides a series of compounds which are useful as inhibitors of phospholipases A2, especially cytosolic phospholipase A2.(FR) L'invention se rapporte à des procédés de traitement ou de prévention de la maladie d'Alzheimer chez un mammifère, ce procédé consistant à administrer à un mammifère nécessitant un tel traitement une dose efficace d'un inhibiteur de phospholipase A2 (PLA2). L'invention se rapporte également à une série de composés aptes à être utilisés comme inhibiteurs de phospholipases A2, en particulier de la phospholipase A2 cytosolique.

  该发明提供了一种治疗或预防哺乳动物阿尔茨海默病的方法，该方法包括向需要治疗的哺乳动物施用有效量的磷脂酶A2抑制剂。该发明还提供了一系列化合物，这些化合物可用作磷脂酶A2的抑制剂，特别是细胞质磷脂酶A2。
• USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE
  申请人：ELI LILLY AND COMPANY

  公开号：EP0735870A1

  公开（公告）日：1996-10-09
• EP0735870A4
  申请人：——

  公开号：EP0735870A4

  公开（公告）日：1998-08-19